5 Stocks with Biggest Upside Potential According to Analysts

Page 5 of 5

1. Vir Biotechnology, Inc. (NASDAQ:VIR)

Number of Hedge Fund Holders: 22

Upside Potential as of July 20: 282.48%

San Francisco, California-based Vir Biotechnology, Inc. (NASDAQ:VIR) is a commercial-stage immunology company focused on the development of therapies to treat and prevent serious infectious diseases. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus.

On July 20, Vir Biotechnology, Inc. (NASDAQ:VIR) announced that the Phase 2 Prevention of Illness Due to Influenza A (PENINSULA) trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints.

Following the announcement, HC Wainwright & Co. reiterated its target price of $100 and a ‘Buy’ rating for Vir Biotechnology, Inc. (NASDAQ:VIR) shares. The analyst believes that the selloff of the company’s shares following the trial miss was ‘overdone’.

As of Q1 2023, Vir Biotechnology, Inc. (NASDAQ:VIR) shares were owned by 22 of the 943 hedge funds tracked by Insider Monkey, with a total value of $161 million. Notable hedge fund investors included Point72 Asset Management, Avidity Partners Management, and Renaissance Technologies, among others.

You may also like to read Nouriel Roubini on Bitcoin and Other Predictions and 10 Best Growth Mutual Funds and Their Latest Top Picks

Page 5 of 5